Leflunomide

来氟米特

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameLeflunomide
Drug Alias Nameleflunomidum来氟洛米leflunomidaAravaRepso +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)CNS Embryonal TumorSolid tumours +[19] 
Global Approved IndicationsLupus NephritisArthritis, RheumatoidArthritis, Psoriatic
Approved Indications in ChinaLupus NephritisArthritis, Rheumatoid
Original Approved Country/TerritoryUnited States
Original Approved Date1998/09/10
Country/TerritoryCzechiaCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesINTERNATIONAL BIO SERVICES CO LTDSanofiSanofi-Aventis Deutschland Gmbh +[7] 
Inactive CompaniesSandozPfizer IncThe University Of Chicago +[6] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursGraft vs Host Disease +[11] 
Inactive IndicationsCNS Embryonal TumorLupus Erythematosus, SystemicSmoldering Multiple Myeloma +[8] 

Other Information

ATC CodeL04AK01
Related LinksWikipediaDrugBankKEGG